Recent News

Through expert second opinions, remote consultations, and visiting programs from leading global institutes, Burjeel Cancer Institute is set to transform the oncology landscape in the UAE 

Abu Dhabi, April 16, 2025: In a major step toward expanding access to world-class oncology services, Burjeel Cancer Institute (BCI), one of the largest cancer care networks in the UAE, has announced strategic collaborations with three globally renowned institutions — the European Institute of Oncology (IEO), the Children’s Hospital of Philadelphia (CHOP), and SJD Barcelona Children’s Hospital — during Abu Dhabi Global Healthcare Week. These partnerships aim to redefine oncology care in the region by advancing clinical services, research, education, and personalized oncology. 

BCI caters to over 5,000 patients each year and provides 360-degree tailored care, from diagnosis to survivorship programs. Its network is spread across the entire UAE, including key locations in Abu Dhabi, Al Ain, Dubai, Sharjah, and Al Dhafra, ensuring access to comprehensive and compassionate cancer care across all ages. 

These new collaborations will leverage teleconsultation and remote patient monitoring technologies, facilitate second opinions from international experts, and establish visiting programs to enable deeper knowledge exchange and enhance local capabilities. 

Enhancing Pediatric Cancer Care 

The Children’s Hospital of Philadelphia (CHOP) collaboration will enhance pediatric cancer care and strengthen capabilities in advanced diagnostics, remote consultations, and multidisciplinary second opinions. Visiting programs from CHOP will support knowledge exchange in subspecialized pediatric oncology. 

Mrs. Madeline Bell – President & Chief Executive Officer (CEO) for Children’s Hospital of Philadelphia (CHOP), said “We are excited to collaborate with BCI in advancing pediatric cancer care through shared expertise, remote care innovations, and training opportunities. Together, we will empower healthcare teams and support families facing childhood cancer.” 

The partnership with SJD Barcelona Children’s Hospital is set to further augment BCI’s capabilities in comprehensive childhood cancer care. The collaboration will offer continuous remote support and medical guidance, particularly for rare and complex pediatric cases. 

Dr. Manel del Castillo Rey – Chief Executive Officer (CEO) SJD Barcelona Children’s Hospital, commented, “Our collaboration with BCI provides a framework for sharing specialized knowledge and co-managing complex pediatric oncology cases. By bridging geographies, we can provide more children with access to expert care.” 

Integrating Global Expertise 

In partnership with the European Institute of Oncology (IEO), BCI will focus on strengthening cancer care in the UAE through clinical and scientific research development, training and education programs for healthcare professionals, and high-level clinical services. The collaboration will also support the creation of a distinguished network of visiting professors, capacity-building initiatives for nurses and pharmacists, and the establishment of a strategic advisory board for BCI. 

Ing. Mauro Melis – Chief Executive Officer IEO & Centro Cardiologico Monzino, said, “Our partnership with Burjeel Cancer Institute reflects a shared commitment to elevating standards in cancer care. Through collaborative research, clinical exchanges, and capacity-building, we aim to jointly accelerate innovation and improve outcomes for patients in the country and across the region.” 

Advancing Diagnostic Testing for Cancer 

In addition to these collaborations, Burjeel Cancer Institute also joined hands with AbbVie Biopharmaceuticals to advance a personalized medicine approach in cancer care. The collaboration aims to support the adoption and access to the latest testing techniques to enhance the diagnosis and treatment of patients with various types of cancer, including ovarian, lung, and colorectal malignancies. 

As part of this initiative, the anatomical pathology laboratory lead by Dr. Rawia Mubarak will introduce a test for the first time in the region for platinum-resistant ovarian cancer, which will help identify patients who may benefit from emerging targeted therapies—offering a more personalized path forward and renewed hope for better outcomes. 

Mr. Mohammad Aboubakr Abdulgawad Mohammad – General Manager for AbbVie Pharmaceuticals, said,“Through our collaboration with Burjeel Cancer Institute, we are proud to introduce this advanced test in the UAE, a critical step toward identifying individuals who may benefit from emerging targeted therapies. By adopting this innovation, physicians can offer a more personalized and effective approach to care.” 

Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, remarked, “These global partnerships are a pivotal step in our mission to bring world-class cancer care to the region. By aligning with some of the most prestigious institutions worldwide, we are building a future-ready oncology ecosystem that prioritizes quality, access, and innovation for every patient we serve.” 

These partnerships underscore BCI’s strategic vision to not only expand its clinical capabilities but also serve as a regional hub for knowledge, innovation, and excellence in oncology. 

The strategic collaboration brings next-gen AI pathology tools to the region, enhancing diagnostic accuracy and access to advanced cancer care 

Abu Dhabi | New York, April 16, 2025: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has announced a strategic partnership with Paige, a US-based leader in next-generation AI technology. The collaboration aims to enhance access to advanced cancer diagnostics by deploying Paige’s AI-powered solutions across Burjeel’s healthcare network. It also seeks to address the global shortage of pathologists and accelerate access to rapid, reliable cancer diagnostics, particularly in underserved communities and emerging markets. The collaboration was announced during Abu Dhabi Global Health week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.  

Paige has developed a suite of AI applications that support diagnostic decision making in cancer pathology. Paige Prostate Detect*, a key component of the suite, is the first FDA-approved AI algorithm, that works by detecting prostate cancer in core-needle biopsies. With this partnership, Burjeel Holdings will become one of the first in the region to offer these AI-powered diagnostic tools, reinforcing its commitment to delivering timely and accessible cancer care. Paige’s solutions are designed to augment the capabilities of pathologists, streamline workflows, and boost diagnostic confidence, ultimately resulting in better outcomes for patients. The partnership represents a significant step toward the democratization of advanced care, ensuring that even the most advanced technologies reach patients who need them most. 

“Our collaboration with Paige represents a transformative step in delivering cancer diagnostics across our network. By incorporating next-gen AI into our pathology services, we aim to enhance the speed and accuracy of cancer diagnosis, enabling more effective treatment decisions. This partnership also reflects our mission to bring world-class, technology-enabled care to emerging markets,” said John Sunil, Group CEO of Burjeel Holdings. 

Paige has earned multiple regulatory achievements in AI for pathology, including FDA Breakthrough Device Designation for Paige PanCancer Detect, Paige Breast Lymph Node, and Paige Prostate Detect. Burjeel Holdings will deploy these AI applications along with Paige OmniScreen, which simultaneously screens over 1,600 molecular biomarkers to support comprehensive cancer diagnosis and more personalized treatment. 

“Burjeel Holdings’ commitment to innovation and equitable care across the MENA region makes them a powerful ally in helping us close diagnostic gaps and bring the benefits of our AI technology to more patients, faster. This partnership helps deliver on our mission to make next-generation cancer diagnostics accessible worldwide and aligns with our vision to standardize access to cutting-edge diagnostics on a global scale,” said Peter Hamilton, General Manager of Diagnostics, Paige. 

The partnership marks a key milestone in positioning Burjeel Holdings as a regional hub for AI-enabled pathology, with the potential to scale this transformative technology across MENA and beyond.  

The agents speak over 15 widely used languages, including the Emirati dialect 

April 17 2025, Palo Alto/Abu Dhabi: In a significant leap towards establishing an integrated innovation ecosystem, Burjeel Holdings and US-based Hippocratic AI have announced a strategic partnership aimed at transforming healthcare delivery through safe, scalable, and empathetic AI at Abu Dhabi Global Health Week. What sets these agents apart is their ability to engage in natural, safety-focused, human-like conversations.  

Through the integration of Hippocratic AI’s multilingual, empathy-driven agents, Burjeel Holdings will deliver real-time, culturally aware support across a wide range of patient touchpoints, including appointment scheduling, patient education, health risk assessments, and follow-up check-ins. These advanced agents are capable of sustained, multi-turn dialogue, enabling them to provide consistent, compliant, and compassionate communication that enhances both the patient experience and care continuity.  

Hippocratic AI’s agents already speak over 15 widely used languages such as Spanish, Mandarin, and Vietnamese, as well as more localized dialects like Emirati Arabic, with plans to expand linguistic coverage to nearly all major global languages. The collaboration will also deliver customized regional generative AI agents tailored for cultural alignment and local relevance, enhancing the quality and empathy of patient interactions. The AI agents will be deployed across key specialties such as oncology, cardiology, neurology, and orthopedics, supporting both clinical and administrative tasks to help streamline operations and elevate the patient experience.  

Hippocratic AI, the company that pioneered the first safety-focused generative AI healthcare agents, recently unveiled its patented Polaris 3.0, its most advanced and safety-focused constellation architecture to date. Built on extensive real-world insights from both patients and healthcare providers. With over 1.85 million patient calls and collaborations with more than 25 healthcare enterprise partners, it has set a new benchmark in patient safety and satisfaction, achieving a clinical accuracy rate of 99.38% and a record-high patient experience rating of 8.95 out of 10. At the core of the Polaris constellation system are specialized supervisor models that oversee critical areas such as medications, labs and vitals, nutrition, escalation protocols, and hospital-specific policies. 

Mr. Munjal Shah, Co-Founder and CEO of Hippocratic AI, said, “We’re proud to partner with Burjeel Holdings, one of the most respected healthcare systems in the region. This partnership supports our shared mission of achieving healthcare abundance. Our empathic genAI agents are designed to create a more compassionate and effective patient experience. Together, we will tailor our solutions to meet the specific needs of the communities we serve.” 

The partnership focuses on expanding the deployment of these genAI healthcare agents across Burjeel Holdings' facilities, ensuring that healthcare providers can access the latest advancements in technology and patient support. Incorporating AI technologies into the complex care environment aligns with Burjeel Holdings' commitment to transforming healthcare delivery across critical areas. 

Mr. John Sunil, Group CEO of Burjeel Holdings, said, "At Burjeel Holdings, we believe that the future of healthcare lies in the perfect harmony between cutting-edge technology and personalized care. Our partnership with Hippocratic AI is a testament to our ongoing mission to leverage AI to improve patient experience, efficiency, reduce wait times, and ultimately provide better health outcomes for our patients."  

This collaboration reflects a shared vision: harnessing safety-focused generative AI to support healthcare systems, ease staffing challenges, and deliver hyper personalized, compassionate care - advancing the collective goal of healthcare abundance. 

• Located within Burjeel Cancer Institute (BCI) at Burjeel Medical City, MBZ, this women-led center is designed as a comprehensive, one-stop destination offering dedicated care under one roof 
• The center emphasizes a patient-centered approach, where same-day appointments are offered, ensuring a diagnosis is provided during the patient’s consultation 

Abu Dhabi, April 21, 2025: Burjeel Cancer Institute (BCI), one of the largest cancer care networks in the UAE, has officially launched Burjeel Breast Center, a first-of-its-kind facility offering comprehensive, multidisciplinary care for women with both malignant and benign breast conditions.  

The Center was launched at a ceremony held in BMC in the presence of Dr. Rashed Obaid AlSuwaidi, Director General Abu Dhabi Public Health Center, H.E. Dr. Fayeza Saif Alyafei, Executive Director of the Healthcare Quality Sector, Department of Health – Abu Dhabi, and Mr. Muhammed Shihabuddin, Group Chief Financial Officer, Burjeel Holdings.  

Located within Burjeel Medical City, the center is designed as a one-stop destination for breast health, integrating advanced diagnostics, personalized treatment, and dedicated support services under one roof. The facility has been designed to offer a seamless breast cancer screening experience—from initial screening to diagnosis and treatment—while reducing anxiety and streamlining the journey to recovery. According to experts, with early diagnosis, breast cancer recovery rates can exceed 95%, making timely intervention critical. The center emphasizes a patient-centered approach, where same-day appointments are offered, ensuring a diagnosis is provided during the patient’s consultation. 

At the heart of the center is a women-led medical team, composed of internationally recognized experts in breast health, including Dr. Nehad Abdul Razzaq Kazim Albastaki Consultant Breast Imaging & Interventional Radiologist, an expert Emirati female doctor specializing in radiology and mammography. This all-female team ensures the highest levels of privacy, comfort, and individualized care for patients. Additionally, a special team specializing in breast reconstruction is available for cases requiring surgery and resection, further enhancing the care provided. At the center, samples are processed and delivered on the same day, ensuring a swift and accurate diagnosis.   

Equipped with cutting-edge technology, including HOLOGIC’s 3Dimensions™ Mammography System, the center offers enhanced imaging for early and accurate detection of breast abnormalities. Additionally, the AI-driven breast radiology system assists radiologists in interpreting mammograms, ultrasounds, and MRIs, ensuring accuracy and reducing the chances of false diagnoses. As part of its comprehensive approach, the center also offers a survivorship program, empowering cancer survivors with the tools, support, and care they need to thrive post-treatment.   

Burjeel Breast Center is launching the first-of-its-kind initiative, the “Survivorship Lounge,” which is dedicated to empowering breast cancer survivors by providing a safe, supportive, and informative space focused on life after treatment. This lounge will offer personalized survivorship care plans, wellness resources, psychological support, lifestyle guidance, and education on long-term health—ensuring that every survivor feels seen, supported, and strengthened throughout their post-treatment journey with dedicated team from physicians, psychologists & breastfeeding cancer survivors volunteers. 

“Burjeel Breast Center reimagines the breast care journey by offering an empathetic, data-driven, and efficient clinical environment. By removing barriers to early detection—such as long wait times and the need for prior appointments—we are empowering women to take charge of their health. Early intervention is key, and our walk-in model ensures no time is lost. To enhance patient experience, we have integrated artificial intelligence into our workflow. The AI system can analyze patients’ genetic and hereditary data, helping determine the most effective treatments based on each patient’s unique characteristics,” said Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute.  

Burjeel Cancer Institute Pharmacy Launched 

Enhancing its holistic approach, Burjeel Cancer Institute (BCI) is also launching Burjeel Cancer Institute Pharmacy. Burjeel Cancer Institute Pharmacy proudly holds the distinction of being the first dedicated cancer pharmacy in the UAE. This specialized pharmacy is designed to cater exclusively to the needs of oncology patients, ensuring they have access to a comprehensive range of medications tailored to enhance their quality of life.  

By focusing specifically on cancer care, the pharmacy aims to provide personalized services, expert advice, and support for patients undergoing treatment. This initiative reflects Burjeel Cancer Institute’s commitment to improving the overall patient journey by ensuring access to essential medicines and resources that can aid in their treatment and recovery. 

“The launch of Burjeel Breast Center reflects our commitment to raising the standard of women’s healthcare in the region. By integrating diagnostics, expert consultation, and treatment into one cohesive space, we are delivering a seamless and supportive experience for patients,” said John Sunil, Group CEO of Burjeel Holdings.  

The establishment of Burjeel Breast Center reinforces BCI’s mission to lead in complex cancer care, setting new benchmarks in clinical excellence and innovation across the UAE and the region. 

• Point-of-Care Production Spearheaded by Burjeel Holdings and Caring Cross Promises Affordable, Accessible CAR-T Therapies for Patients in the MENA and Beyond  
• The Collaboration was Announced at Abu Dhabi Global Health Week 

Abu Dhabi, April 15, 2025: In a groundbreaking move set to transform cancer treatment access across MENA, Burjeel Holdings has partnered with U.S.-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs. Caring Cross will support Burjeel Holdings with the necessary technology, materials, and specialized training to establish a local ecosystem for manufacturing CAR-T therapies, as well as providing lentiviral vectors essential for clinical development. The collaboration was announced at Abu Dhabi Global Health Week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.   

CAR-T therapies, which reprogram a patient’s immune cells to attack cancer cells, have shown remarkable success in treating certain blood cancers like leukemia and lymphoma. However, with costs ranging from US$350,000 to over $1 million in global markets, access remains severely restricted. The partnership seeks to dismantle this barrier by enabling the production of CAR-T therapies at a fraction of the current price, making these treatments accessible to a vastly broader patient population in MENA and beyond. 

Enhancing Access to Life-Saving Cancer Care 

The collaboration will position Burjeel Holdings as a regional hub for advanced cell and gene therapies. By enabling local, point-of-care production of patient-specific therapies, the initiative will expand the reach of these therapies to underserved populations across the MENA region. The first phase of the program will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future. 

“We are honored to partner with Caring Cross, whose expertise in CAR-T cell therapy production technology will enable us to provide affordable, life-saving treatments to our communities and beyond. This partnership is a pivotal step in our commitment to advancing medical innovation and expanding access to critical healthcare services,” said John Sunil, Group CEO of Burjeel Holdings. 

“We are excited to partner with Burjeel Holdings to improve access to CAR-T cell and other ATMPs for patients across their hospital networks in the MENA region,” said Boro Dropulić, Executive Director of Caring Cross. “This collaboration advances our mission to make these groundbreaking treatments accessible and affordable around the world. By combining our innovative technologies with Burjeel Holdings hospital network and infrastructure, we intend to significantly improve patient access with a sustainable and cost-effective model.” 

Building Local Capabilities and Expanding Impact 

This initiative reflects Burjeel Holdings’ broader mission to expand access to high-quality healthcare in regions that need it most. The partnership will focus on training and developing local healthcare providers, ensuring the sustainable and scalable delivery of CAR-T therapies across MENA, India, and globally.  

“Our collaboration is operating at the cutting edge of medical innovation, opening doors to biological therapies not just in MENA, but also in emerging markets like India and other parts of Asia. This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced healthcare globally,” said Dr. Ajlan Al Zaki, Director of the Hematology Oncology & Cellular Therapy Center at Burjeel Hospital Abu Dhabi. 

This partnership reinforces Burjeel Holdings’ commitment to transforming the healthcare landscape in MENA and beyond, offering hope and tangible solutions to millions of patients who previously lacked access to life-saving treatments. 

• Acquires 80% stake in Dubai-based Advanced Care Oncology Center  
• Announces plan to launch ACOC-branded radiation oncology centers across GCC 

Abu Dhabi, UAE, February 18, 2025: Burjeel Holdings PLC (“Burjeel” or “the Group”), a leading super-specialty healthcare provider in the MENA region, listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), has announced its plan to establish the leading radiation oncology network in the GCC, following its successful acquisition of an 80% stake in the Dubai-based Advanced Care Oncology Center (ACOC), renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services.This transformative initiative aims to redefine cancer care delivery in the region, leveraging ACOC’s expertise to build a network that ensures accessible and advanced oncology treatment. 

Oncology Global & GCC Landscape 

Globally, cancer cases are projected to increase significantly, driven by aging populations and lifestyle changes. According to the World Health Organization, annual global cancer diagnoses are expected to rise from 20 million in 2024 to over 30 million by 2040, highlighting the growing global burden of cancer. 

In the GCC, the oncology landscape presents both challenges and opportunities. Cancer cases in the region are anticipated to grow by approximately 50% over the next two decades, driven by similar demographic and lifestyle trends. However, the region faces a critical shortage of cancer care infrastructure to manage the growing cases, leading to substantial unmet demand for specialized oncology services. This highlights the immense potential for Burjeel Holdings to expand its oncology platform, ensuring timely and effective cancer treatments to meet regional healthcare needs. 

Additionally, the growing adoption of advanced oncology solutions, such as radiation therapy, robotic surgical oncology, and precision medicine, demonstrates a clear trend towards innovative and specialized care pathways in the GCC. 

Driving Cancer Care Leadership in the GCC 

The planned ACOC-branded network aims to strategically improve oncology access  in underserved markets across the GCC.  

• Enhance Accessibility: The stand-alone ACOC centers will serve as trusted hubs for radiation therapy, expanding patient access to specialized care in underserved regions across the UAE and the GCC. 
• Integrate Advanced Technology: Each center will be equipped with cutting-edge technologies, including state-of-the-art LINAC systems, AI-driven radiation planning, and precision imaging tools.  
• Streamline Referrals: By offering focused and dedicated radiation therapy services, ACOC-branded centers will establish a robust platform for referrals from a broad network of healthcare providers. 
• Support Burjeel Cancer Institute: The network will support Burjeel Cancer Institute (BCI), the Group’s hub for advanced cancer treatments. Patients requiring surgical oncology, immunotherapy, robotic surgery, and bone marrow transplants will benefit from a smooth and integrated transition to the Group’s comprehensive, cutting-edge care. 
• Foster Research & Innovation: Leveraging the Oracle Health EMR implementation for its diverse patient base, the network will drive medical research and data-driven innovations, further solidifying Burjeel’s leadership in preventive oncology and precision medicine. 

Further information, including details of the expansion plan, will be disclosed in due course. 

Burjeel Cancer Institute: Anchor of Burjeel’s Oncology Platform 

This acquisition is a strategic fit for the Group’s growing oncology platform, anchored by BCI,  one of the UAE’s largest cancer care networks. With facilities spanning Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai, the Group delivers integrated and comprehensive oncology services. These include medical oncology, radiation therapy, robotic surgical oncology, bone marrow transplants, and palliative care. The integration of ACOC into Burjeel’s ecosystem will enhance synergy between stand-alone radiation oncology centers. This structure ensures a streamlined and efficient care pathway, where referrals to the Group are directed toward highly specialized treatments, complementing the network’s broader accessibility and outreach.    

Mr. John Sunil, Group CEO of Burjeel Holdings, said: “Our vision is to establish a comprehensive and advanced oncology network in the GCC, addressing unmet needs in specialized cancer care. By building on ACOC’s legacy of excellence, we will bring accessible, high-quality radiation oncology services closer to patients, significantly enhancing cancer care outcomes across the region. This network will not only support early intervention and treatment but will also connect seamlessly with the Burjeel Cancer Institute for advanced therapies.” 

ACOC Transaction Highlights 

• Value Transaction: Burjeel has acquired an 80% equity stake in ACOC for AED 92 million on a cash-free, debt-free basis, with an option to acquire the remaining stake. ACOC recorded revenue of AED 64 million in 2024. 
• Continuity of Leadership: ACOC’s Founder and CEO, Bashir Abou Reslan, retains a 10% stake and continues to lead the center’s operations, ensuring continuity and excellence in patient care. The remaining 10% continues to be held by Raphael Khlat Middle East FZCO, an existing shareholder. 

About Burjeel Holdings  

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 100 assets across the UAE, Oman, and Saudi Arabia, including 19 hospitals, 29 medical centers, 29 physiotherapy and wellness centers, 15 pharmacies, and other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel. 

About Advanced Care Oncology Center 

Established in 2017, ACOC is a trusted provider of integrated cancer care services in Dubai. The center is renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services. ACOC’s commitment to clinical excellence is underscored by its accreditations, including the Gold Accreditation from Accreditation Canada, awarded in August 2021. It is the only facility in the UAE to hold PET/CT EARL Accreditation from the European Association of Nuclear Medicine (EANM). Additionally, ACOC received the Certificate of Medical Prescription Audit from Bienzobas in Spain in October 2021, demonstrating compliance with European regulatory standards such as EMA guidelines and international protocols from NICE and NCCN. 

Contacts 

The Orthopedic Residency and Hematology-Oncology Fellowship programs will equip physicians with the expertise needed to meet global healthcare standards

Abu Dhabi, February 15, 2025: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has achieved a significant milestone in healthcare education by receiving accreditation from the National Institute for Health Specialties (NIHS), a prestigious accreditation program in the UAE. The two specialized medical training programs—Orthopedic Residency and Hematology-Oncology Fellowship—have secured this accreditation. The Hematology-Oncology Fellowship marks a milestone for Burjeel Holdings as the first healthcare provider in the UAE to achieve this recognition, while the accreditation for the Orthopedic Residency sets a precedent in Abu Dhabi’s private healthcare sector.

The accreditation was officially conferred by Dr. Mohammed Al Houqani, Secretary General of NIHS during a ceremony attended by Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, H.E. Dr. Rashed Alsuwaidi, the Acting Director General of Healthcare Regulatory at Department of Health – Abu Dhabi, Mr. John Sunil, Group CEO of Burjeel Holdings, and Mr. Safeer Ahamed, Group Co-CEO of Burjeel Holdings.

Dr. Mohammed Al Houqani praised Burjeel Holdings’ role in advancing medical education, highlighting its significant contributions to training the healthcare workforce and equipping them with the highest global standards. He emphasized the Group’s efforts in creating an ideal training environment based on best medical practices, which will strengthen the healthcare sector with specialized and qualified physicians capable of delivering high-quality medical services for healthcare challenges.

Speaking about this achievement, Dr. Tahani Al Qadiri, Group Director of Emiratization and Academics at Burjeel Holdings, said that this accreditation is a testament to Burjeel’s commitment to raising the next generation of specialized healthcare professionals in the region. “This milestone not only strengthens our position as a leader in private-sector medical education but also contributes significantly to Abu Dhabi’s healthcare ecosystem by nurturing highly skilled specialists,” she added.

These specialized programs will provide rigorous, hands-on training for medical residents and fellows, equipping them with the expertise required to meet global healthcare standards. The Orthopedic Residency Program will prepare aspiring trainees with comprehensive clinical experience, while the Hematology-Oncology Fellowship Program will cultivate highly specialized expertise in cancer care.

According to Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, the initiative will contribute to better patient outcomes. “By establishing the first accredited Hematology-Oncology Fellowship Program in the private sector in the country, we are creating a structured pathway for developing highly skilled oncologists who will play a crucial role in enhancing cancer care in the region,” he said.

Dr. Mohamed Muath ADI, Consultant Orthopedic Surgeon at Burjeel Medical City (BMC) and Program Director of the Orthopedic Residency Program, said that this milestone will enhance the quality of orthopedic education and training in the region, further elevating the standard of orthopedic care in the UAE.

This accreditation, aligning with the UAE’s strategic vision to advance the healthcare sector, reflects Burjeel’s commitment to advancing medical education, and positioning Abu Dhabi as a hub for world-class medical training.

The new center reflects Burjeel’s ongoing commitment to expanding its services and meeting the growing healthcare needs of the community with integrated, world-class medical care

Al Ain, February 11, 2025 – Burjeel Cancer Institute (BCI), the largest cancer care network in the UAE, has expanded its reach by opening a new center at Burjeel Hospital Al Ain. This strategic expansion reinforces Burjeel Holdings’ commitment to providing world-class oncology services across the country, ensuring advanced cancer care is accessible to more patients.

The inauguration ceremony was attended by Mr. John Sunil, Group CEO of Burjeel Holdings, along with distinguished guests from the Al Ain Traffic Police, Abu Dhabi Agriculture and Food Safety Authority, and Al Ain Civil Defense.

BCI, the oncology arm of Burjeel Holdings, operates from its flagship facility, Burjeel Medical City in Abu Dhabi. At the forefront of oncology treatment and research, BCI brings cutting-edge therapies and a multidisciplinary approach to patient care. The new center at Burjeel Hospital Al Ain reflects its commitment to expanding services and meeting the community’s growing healthcare needs with integrated, world-class medical care.

The newly opened center in Al Ain offers a full spectrum of oncology services, including expert consultations, state-of-the-art diagnostic capabilities and specialized treatments such as chemotherapy, immunotherapy, and targeted therapies. The institute also provides comprehensive surgical oncology services, performed by a team of leading specialists utilizing the latest medical technologies to ensure precision and efficiency. To enhance patient comfort and privacy, the facility features dedicated chemotherapy suites, creating a supportive and personalized treatment environment. The seamless integration of these services ensures that patients receive a holistic care experience, from diagnosis through recovery.

Professor Humaid bin Harmal Al Shamsi, Consultant Oncologist and CEO of Burjeel Cancer Institute, emphasized the significance of this expansion.

“The opening of BCI in Al Ain reflects our commitment to expanding oncology services and making specialized cancer care more accessible across the UAE. Our goal is to bring high-quality, patient-centered treatment closer to those in need, ensuring that individuals in Al Ain have access to the latest advancements in cancer care without the need to travel far.”

“At BCI, we prioritize a seamless patient journey from diagnosis to treatment and recovery, with a multidisciplinary approach that enhances outcomes and quality of life. To further ease access to care, we welcome patients for consultations without requiring prior appointments, reinforcing our mission to provide an integrated and patient-first experience,” he said.

Dr. Aysha Almahri, CEO - Al Ain Region, Burjeel Holdings, highlighted the institute’s impact on cancer care in the region.

“At Burjeel, we recognize that the foundation of a thriving society lies in the health and well-being of its people. Cancer care is a top priority, and this expansion ensures that more patients have access to cutting-edge therapies, reducing the need for medical travel. With the establishment of BCI in Al Ain, we reaffirm our commitment to providing world-class oncology treatments to patients across the UAE.”

With the launch of the new center in Al Ain, Burjeel Holdings continues to redefine oncology care by offering patients state-of-the-art treatment options, further solidifying the UAE’s position as a regional leader in specialized cancer care.

The lab is dedicated to the comprehensive diagnosis, treatment, and rehabilitation of balance and vertigo disorders

Abu Dhabi: Burjeel Medical City (BMC), the flagship facility under Burjeel Holdings, has unveiled a state-of-the-art Balance Lab within the Burjeel ENT Head & Neck Institute. This new facility is dedicated to the comprehensive diagnosis, treatment, and rehabilitation of balance and vertigo disorders, further strengthening BMC’s advanced offerings in otolaryngology (ear, nose, throat) and head & neck surgery.

The Balance Lab was officially opened in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. John Sunil, Group CEO of Burjeel Holdings, alongside Dr. Mujtaba Ali Khan, CEO of BMC, and other senior officials.

The Balance Lab was officially opened in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. John Sunil, Group CEO of Burjeel Holdings, alongside Dr. Mujtaba Ali Khan, CEO of BMC, and other senior officials.

Specialized Focus on Balance and Vertigo Disorders

Designed to address a wide range of balance and vertigo conditions affecting all age groups, the Balance Lab utilizes a structured testing protocol to accurately diagnose and quantify the underlying causes of dizziness and imbalance. These conditions can result from various factors, including inner ear disorders, neurological issues, strokes, muscle weaknesses, and peripheral neuropathy.

Designed to address a wide range of balance and vertigo conditions affecting all age groups, the Balance Lab utilizes a structured testing protocol to accurately diagnose and quantify the underlying causes of dizziness and imbalance. These conditions can result from various factors, including inner ear disorders, neurological issues, strokes, muscle weaknesses, and peripheral neuropathy.

Designed to address a wide range of balance and vertigo conditions affecting all age groups, the Balance Lab utilizes a structured testing protocol to accurately diagnose and quantify the underlying causes of dizziness and imbalance. These conditions can result from various factors, including inner ear disorders, neurological issues, strokes, muscle weaknesses, and peripheral neuropathy.

Advanced Hearing Aid Services

In addition to balance services, the institute has introduced a hearing aid booth equipped with advanced technologies, offering patients a range of hearing aids and comprehensive services including fitting, calibration, programming, troubleshooting, ear molds, swim plugs, and tinnitus masking devices. This addition enhances the clinic’s ability to provide personalized and efficient hearing care.

The introduction of advanced technologies and services in the balance lab and hearing aid booth is expected to bring significant improvements in patient care across several dimensions, including diagnosis accuracy, treatment outcomes, patient engagement, and overall patient experience.